Definitive Healthcare Corp.

to definitive healthcare first quarter 2022 earnings conference call. At this time, all participants are in a listen mode, listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, David Samuels, General Counsel. Thank you, and over to you.

Good afternoon, and thank you for joining us today to review Definitive Healthcare's first quarter 2022 financial results. Joining the call today are Jason Krantz, Definitive Healthcare's founder and CEO, Robert Musselwhite, Definitive Healthcare's president, and Rick Booth, Definitive Healthcare's chief financial officer. During this call, we will make forward-looking statements, including, but not limited to, statements relating to our markets and future growth opportunities, the benefits of our healthcare commercial intelligence solutions, our competitive position, customer behaviors, our financial guidance, our planned investments, and the anticipated impact from the COVID-19 pandemic on our business and results of operations, as well as on our clients, the healthcare industry generally, and the macroeconomic environment. Any forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties, including those discussed in the risk factor section of our filings with the SEC. Actual results may differ materially from forward-looking statements. The company undertakes no obligation to revise or update any forward-looking statements to reflect events that may arise after this conference call, except as required by law. For more information, please refer to the cautionary statements included in the earnings release that we just posted to the investor relations portion of our website. Additionally, we will discuss non-GAAP financial performance measures on this conference call. References on this call to profitability are on an adjusted EBITDA basis. Please refer to the tables in our earnings release on the investor relations portion of our website for a reconciliation of these measures to the most directly comparable GAAP financial measures. With that, I'd like to turn the call over to Jason.

Thanks, David. I would like to thank all of you for joining us this afternoon to discuss definitive health care's first quarter results. Before we go into more details on the quarter, I want to comment quickly on the news that went out today at the same time as our earnings press release. As you've likely read by now, I'm excited to announce that Robert Musselwhite, our current president, will become the Chief Executive Officer of Definitive Healthcare, effective August 1st, 2022. At that time, I will move into the role of Executive Chairman. This transition is exciting for the company and for me. For the company, Robert brings a wealth of healthcare industry expertise and a deep familiarity with running a public, healthcare-focused SaaS company. He is the perfect person to lead Definitive Healthcare through our next period of growth. On a personal level, transitioning to the executive chairman role will let me focus my attention on parts of the business I'm most passionate about, specifically product development and strategy, while still partnering with Robert on broader, long-term company strategy and mergers and acquisitions. Robert and I have developed a fantastic partnership over the last almost year working together, and I'm excited about continuing our partnership to take definitive healthcare to the next level. Now, let's get back to our Q1 results. We got off to a strong start in 2022, with important wins across each of our core markets and continued progress on our innovation roadmap. Our performance demonstrates the significant market opportunity for healthcare commercial intelligence, which we deliver through our comprehensive SaaS-based platform, our industry-leading data, and our proprietary data science-based analytics. We are at the very early stages of a $10 billion in growing market opportunity, and we believe that we are in a great position to generate strong growth and significant profitability for years to come. Let's start today by quickly reviewing our financial results for the quarter, which was highlighted by the company crossing $200 million in annualized revenue for the first time. Our total revenue was $50.1 million, which represents 36% year-over-year growth. And our adjusted EBITDA was 14 million, which translates into a 28% margin. These impressive results reinforce our ability to generate high growth and substantial profitability while at the same time investing organically and inorganically to support our long-term objectives. I'm now going to hand it over to Robert to talk more about some of the drivers of the success, as well as to highlight some key customer wins during the quarter.

Thanks, Jason. Before I comment on our business strategy and customer wins, I want to say that I'm tremendously excited to move into the CEO role at Definitive Healthcare. I'm passionate about the company's mission to transform data, analytics, and expertise into healthcare commercial intelligence, and I'm a big believer in the company and the culture that Jason and all the employees have built. We have a fantastic opportunity in front of us. I also want to take a moment and thank Jason for his outstanding leadership over the past 11 years. It's the rare CEO who can start a company and lead it past 200 million in annualized revenue and through an IPO. I look forward to continuing to partner with Jason in his new role as executive chairman to take definitive healthcare to the next level. Now I'd like to spend a few minutes providing some details on the deep competitive differentiation that definitive healthcare has developed over the past 11 years. As we've discussed in the past, the $4 trillion US healthcare market is incredibly complex and difficult to navigate effectively. Our mission is to simplify this complexity for any company doing business anywhere within the healthcare ecosystem, and we believe we do this better than anyone else. We believe our differentiation stems from three key factors. The first is that we are the only company that can provide complete coverage of the entire healthcare ecosystem. Over the past 11 years, we have leveraged powerful data science and engaged in extensive proprietary research. that has enabled us to have nearly 100% coverage of all aspects of the healthcare market, physicians, hospitals, imaging centers, clinics, home health agencies, and other entities. We have built a sophisticated data ingestion engine powered by proprietary artificial intelligence that enables us to collect data from more than 270,000 distinct companies, 125,000 public sources, and 25,000 government sources. all of which is then augmented and enhanced through more than 4 million personal interactions each year with participants in the healthcare ecosystem. We also append a large volume of claims data to our proprietary data, sourced from our increasing number of relationships with third-party data providers. Each of these data sets has different rules, structures, and schemas. Our automated platform can understand all of these formats and clean, standardize, and curate the data, And then we used advanced data science to discern new relationships between the different pieces of data, which in turn become new data and intelligence for our customers to use. Our second point of differentiation is our proprietary affiliation mapping. With our expansive view of the market and comprehensive data sets, we're uniquely able to provide insight into the interconnected multi-tiered affiliations that exist among physicians, physician groups, hospitals, imaging centers, ambulatory surgery centers, and other players in the healthcare ecosystem. Many of the legacy vendors in the market offer only claims data. This claims-centric approach provides an incomplete and often skewed view of the market. In fact, nearly half of healthcare facilities in the U.S. do not file claims. If a company is developing a new drug, it can use claims to identify the volume of potential patients. However, it's equally important to understand the hospitals and physician groups where these patients received care in order to understand how this volume aggregates across organizations, how a patient moves through the healthcare ecosystem, and when a patient receives care outside of a network. Our affiliations data helps answer all of these essential questions. Our affiliations data is expressed through our proprietary definitive ID, which helps our clients understand the complex interconnections of the healthcare ecosystem. Similar to a Dun & Bradstreet number, which assigns an industry standard unique identifier for a commercial legal entity in the United States, We assign a definitive ID to every participant in the healthcare ecosystem, including physicians, facilities, integrated delivery networks, and GPOs. The definitive ID is the industry standard for organizational structures in the U.S. healthcare market. Our third vector of differentiation is our ability to continually accelerate innovation by creating new intelligence that doesn't exist elsewhere. With more than half a petabyte of historical data collected over 11 years, we believe we have by far the broadest and most comprehensive healthcare commercial data set in the market. This data set provides us with an unmatched ability to perform sophisticated data science to quickly create new, unique intelligence for our clients. A great example of this is our physician prescribing behavior analytics capability, which helps our customers determine the physicians that are most likely to influence new prescription volume or when and if they may look to switch to a new brand. Another one is the telemedicine propensity score that we were quickly able to introduce after the onset of COVID-19. We were able to rapidly provide an easy to understand metric that showed customers which physicians and facilities had already adopted telemedicine and which ones were highly likely to do so in the future. What makes these two examples so powerful is that these types of analytics are only possible because we have 11 years of longitudinal data that we can leverage to create new intelligence not found elsewhere. Our scale across depth and time is not something that can be easily or quickly replicated. When you put all this together, the result is the only true 360-degree view of the healthcare ecosystem, which provides clients with not only a strategic view of the overall market, but the tactical intelligence that they need to find the right person or institution to target. This helps our clients win in the healthcare market, whether that means accelerating their drug development processes, identifying the right patients for a new medical device, or figuring out which hospitals are expanding and need certain construction equipment. Now I'd like to spend a few moments highlighting some of our key wins in the quarter, which are a great demonstration of the variety of ways new and existing customers are utilizing the definitive healthcare platform and continue to provide tangible evidence of our differentiation. We had several big wins in our life sciences sector in Q1, and the one that I'd like to highlight is a 10,000 employee global medical device company focused on interventional urology, wound care, and ostomy. This client signed a multi-year enterprise deal to segment the market and understand the specific physicians and integrated delivery networks that prescribe its devices. It will use definitive healthcare claims data, affiliations data, and analytics to search for specific HCPCS and CPT codes across all three product lines and then track the patient journey for its products across multiple facilities and providers. In the provider market, we had a significant win with an integrated delivery network that includes 39 hospitals and 163 ambulatory and post-acute facilities across multiple states. This customer signed a multi-year enterprise deal to use definitive healthcare data and analytics in its corporate strategy group, its nursing call and transportation team, and its newly formed group purchasing organization. The organization subscribed to multiple modules in the definitive healthcare platform. As usual, we also sold to all sorts of diversified customers who seek to sell their goods or services into the U.S. healthcare market. We had a big win at the commercial division of one of the largest security services companies in the U.S., and we added a new customer which specializes in floor cleaning and sterilization and is now expanding into cleaning surgical robots. We also had many wins at staffing agencies, both large and small, that are sourcing physicians to meet the needs of the white-hot labor market for healthcare providers. Finally, we started to see an emerging trend of pre-commercial international companies purchasing a definitive healthcare subscription to help them enter the United States market, including a pharmaceutical company based in the Netherlands that is developing a new drug for sepsis. On the upsell side, we had another successful quarter across all of our markets. One of those wins significantly expanded our footprint in a Fortune 10 company, which is building a substantial franchise for kidney care and dialysis. This client added our medical claims and pharmacy claims products, along with our hospital data, to its existing subscriptions to our physician and physician group products. With this enhanced data set, this client can now fully understand the market for its end-stage renal disease and dialysis products, including which facilities and physicians make up the best targets. We also had a major upsell win at the second largest pharmaceutical company in Japan that does a significant amount of business in the United States. This company already subscribed to our hospital and physician data modules, and in the first quarter, it added our medical and pharmacy claims. The company developed treatments for breast cancer and acute myeloid leukemia and wanted to search physicians and hospitals treating specific claims codes. Armed with this intelligence, it will analyze the density of physicians and referral patterns in each sales territory and then use the results to optimize its territories. We are incredibly proud of the amazing and unique asset we have built at Definitive Healthcare and the value we deliver to customers. And we are just getting started. I'd like to turn it back to Jason to talk about some of our recent exciting product innovations.

Thanks, Robert. We had a very active first quarter on the product development front, most notably with the introduction of the Passpart Analytics Suite. Built on the powerful analytics engine we acquired with Analytica Wizards in February, We believe the Passport Analytics Suite is a game changer to the Life Sciences customers. For the first time, Life Sciences customers can optimize their entire commercialization process, all the way from early stage business planning to real-time product performance and marketing optimization to drive superior post-launch results. One of the most exciting aspects of the Passport Analytics Suite is that we now enable Life Sciences customers to integrate virtually any internal or third-party data source into our platform, and run on-demand analytics at scale. The suite can integrate internal sales and marketing data, as well as third-party big data on claims, EMR, lab data, diagnostics data, as well as data from Definitive Healthcare's proprietary platform, including the Definitive ID and our industry-leading provider reference and affiliation data. The Passport Analytics Suite is comprised of two modules, Planning and Performance and Promotional Analytics. Passport planning and performance optimizes the pathway to FDA approval and subsequent commercialization by improving market opportunity selection, accelerating clinical trials, and informing business decisions. Passport promotional analytics helps life sciences organizations maximize revenue and profit by improving customer segmentation, maximizing impact of promotional tactics, and effectively allocating omnichannel budget. We've gotten off to a strong start with Analytica Wizards, which continued its impressive track record of success as it won a big deal at a large 10,000 employee pharmaceutical company. This company purchased Passport Promotional Analytics to consolidate data about its global marketing spend into a single location and then run on-demand analytics to better allocate its investments and maximize the marketing return. Analytica Wizards also upsold incremental business to several of its existing biopharma customers, including a new subsidiary focused on HIV treatment at a top 10 biopharma company. I'm very proud of the Definitive Healthcare and Analytica Wizards teams for working together to seamlessly bring this innovation to market so quickly. The Passport Analytics Suite is a great example of our innovation flywheel at work and our ability to leverage our proprietary assets to expand our value proposition and create future upsell opportunity. We are looking forward to sharing more detail on our product innovation roadmap next month at our second annual user conference, Definitive Live, which will be held virtually on May 17th. I invite all of you to listen to our keynote addresses and panels to get a deeper understanding of our product portfolio, competitive differentiation, and key R&D priorities for the future. Before I turn it over to Rick, I want to reinforce just how powerful and differentiated the Definitive Healthcare platform is. Our customers continually tell us that there is nothing on the market that can provide the critical healthcare commercial intelligence that they need to drive profitable growth across the entire commercialization value chain. I'm incredibly proud of what we have built at Definitive Healthcare, and I want to thank all the employees for their hard work. You are a world-class team that is doing great things for our customers every day. With that, let me turn the call over to Rick to review our financial results in more detail. Rick?

Thanks, Jason. Q1 was another strong quarter, highlighted by rapid revenue growth and strong profitability. I'll start my remarks with a quick overview of our business model from a financial perspective then provide a detailed review of our quarterly results before finishing with our outlook for Q2 and full year 2022. As always, in all my remarks, I'll be discussing our results on a non-GAAP basis, unless otherwise noted. First, let me remind everyone of some of the key attributes that make Definitive Healthcare's business model so compelling. We are a high-growth subscription business, selling into a $10 billion and growing total addressable market, with low single-digit market penetration. We have excellent forward-looking visibility through our multi-year contracts and high net dollar retention rates. We operate profitably with high gross margins and a very efficient customer acquisition engine. We innovate efficiently by building on our proprietary data assets and data science platform. And finally, upfront billings and low CapEx requirements help us translate profits directly into cash flow and shareholder value. Our Q1 results illustrate how this business model plays out in practice. Highlights include 36% revenue growth compared to Q1-21, 28% adjusted EBITDA margin, a 34% unlevered free cash flow margin over the prior 12 months, and revenue growth plus trailing 12-month unlevered cash flow margin was 69%, putting us well above the rule of 40. We believe this combination of high growth, high visibility, and attractive profitability positions us well both in current conditions and for many years ahead. Turning to our results in more detail, revenue for the fourth quarter was $50.1 million, up 36% from prior year, and 4% above the midpoint of our guidance. Our revenue growth continues to be driven by strong sales momentum, particularly among enterprise customers. We ended the quarter with 447 enterprise customers, which we define as customers with at least $100,000 per year of annual recurring revenue. This was an increase of 127 customers, or 40%, year over year, and up 30 from the previous quarter. As a reminder, enterprise customers represent the majority of our ARR, and are a key focus of our go-to-market programs. Our total customer count, which includes smaller customers, was 2,944 at the end of Q1, up from 2,635 in Q1 of 2021. We also continue to have success upselling into our existing customers, which is a core component of our growth strategy. We have best-in-class retention rates among enterprise customers and multiple avenues to increase their spending with us over time. through both the adoption of additional modules and expanding usage to additional users and new areas within their organizations. Gross profit was $44.1 million, up 36% from the first quarter of 2021. Gross margin of 88% was then changed from prior year because investments to add prescription claims data and the acquisition of analytical wizards offset our natural scale effects in the short run. In the remainder of 2022, we expect to see a further 100 to 200 bps downward impact on gross margin as we add additional prescription data sources and as analytical wizards grows. Prescription data represents a significant opportunity to innovate and expand our upsell opportunity within life sciences, and we fully expect to realize operating leverage from these investments over time as we did with medical claims. Sales and marketing expense was $17.5 million, up 51% year over year. And as a percentage of revenue, sales and marketing expenses were 35% of revenue, up from 31% in Q1 of 2021. We're committed to investing for growth. specifically expanding our digital marketing capabilities and building out our sales and customer success teams. We have a highly efficient and scalable go-to-market model with a 10x LTV to CAC ratio, and we will continue to invest incremental resources into our growth initiatives to capture more and more of this $10 billion market for as long as we continue to generate strong returns. Product development expense was $5.5 million. up 49 percent from Q1 of 2021. And as a percentage of revenue, product development expense was 11 percent of revenue, up from 10.1 percent in Q1 of 2021. Investing in our platform and using our existing data assets to launch or enhance multiple products is a highly effective and efficient way for us to increase the value we deliver to customers. We will continue to invest in our product development efforts given the number of exciting opportunities we've identified in our long-term product roadmap. G&A expense was $7.3 million, up 117% from Q1 2021 when we were a private company. As a percentage of revenue, G&A expenses were 14.6% of revenue, up from 9.1% in Q1 2021. The increase in G&A expense reflects incremental public company expense, and the annualization of these largely fixed costs will provide operating leverage throughout the upcoming year and beyond. Operating income was $13.2 million, down 2% from Q1 of 2021. As a percentage of revenue, operating income was 26% of revenue compared to 36% in Q1 of 2021. The year-over-year change in margin is related to three key investments. First, 350 bps of continued investment in sales and marketing. Second, 100 bps of innovation investments in prescription data and in development. And third, 550 bps of increased G&A costs required to operate as a public company. A brief comment on operating income in the quarter. We set very aggressive hiring goals. We're getting really great people, and we're fully staffed with quota carriers. But the pace has been running slower than anticipated in some technology roles, which drove short-term favorability and margins. With the ability to recruit talent in more markets via both analytical wizards and in virtual roles, we plan to make up the shortfall in the remainder of the year. Adjusted EBITDA was $14 million, consistent with Q1 of 2021. As a percentage of revenue, adjusted EBITDA was 28% of revenue, compared to 38% in the prior year due to the investments outlined earlier. As we move through the year, we will see adjusted EBITDA and adjusted EBITDA margins expand as we drive operating leverage from these largely fixed investments noted previously. Net income in Q1 was $7.8 million, or 5 cents per delivered share, based on 154.2 million weighted average shares outstanding. Turning to cash flow, Definitive's high margins, upfront billing, and low CapEx requirements provide substantial free cash flow generation. We focus on trailing 12-month cash flows due to seasonality. unlevered free cash flow with $60.4 million, or a 34% unlevered free cash flow margin on a trailing 12-month basis, converting more than 100% of our TTM-adjusted EBITDA of $56 million into cash. We expect this ratio to return closer to 100% on a TTM basis by the end of the year as we make payments to acquire additional sources of prescription drug data. On the balance sheet, We ended the quarter with $339 million of cash and investments, and with only $269 million of debt and strong profitability, we are well positioned to fund both organic and inorganic growth initiatives. To hedge the risk of rising interest rates on our debt, we entered into a swap to fix the interest rate on $136 million of our term loans through March of 2025. Full details of the terms and the resulting rates are in the supplemental slides up on our website, as well as in our 10Q. Current revenue performance obligations of $160.9 million were up 35% year-over-year, and total revenue performance obligations were up 40% year-over-year. Deferred revenue of $94 million was up 31% from $71.6 million in prior year, And this increase in deferred revenue was slightly smaller than normal because several million dollars of contracts were signed on the last day of the quarter, but not invoiced until April. Revenue performance obligations are unaffected, which underscores why we focus on that metric. We view our strong balance sheet and ongoing profitability as a strategic asset in today's dynamic environment. Turning to analytical wizards, It's early days and they're a small tuck-in, so I won't spend much time on them other than to say that their performance is well aligned with expectations, our sales teams are bullish on the new capabilities, and we're moving swiftly on immigration. I'd like to wrap up by providing our guidance for the second quarter and full year. As always, guidance excludes any new M&A or changes in capital structure. And in general, to the extent that we overperform on revenue, we will seek to reinvest upside in incremental growth opportunities rather than maximizing short-term profitability, although that will vary quarter to quarter. In the second quarter, we expect total revenue of $53 to $54 million for a median growth rate of 34%, non-GAAP income from operations of $13 to $14 million, adjusted EBITDA of $14 to $15 million for a 27% median EBITDA margin and non-GAAP net income of $7 to $8 million or 4 to 5 cents per diluted share on 154.8 million weighted average shares outstanding. For the full year 2022, we're raising full year revenue expectations by $2.5 million to a range of $220.5 million to $224.5 million for a median growth rate of 34%. We are reiterating the profitability guidance we laid out on our last call, which called for non-GAAP income from operations of $57 to $63 million, adjusted EBITDA of $61 to $67 million for a full-year median margin of 29%, a non-GAAP net income of $35 to $41 million, and earnings per share of $0.22 to $0.26 on 155.1 million weighted average shares outstanding. We're pleased with our overperformance on both top line and bottom line and are confident in our full year outlook. Nonetheless, reiterating and not raising our profitability guidance provides flexibility to respond to attractive opportunities to expand our vision on prescription drug data, drive product innovation for providers, and continue to support sales and marketing, while exiting the year with Q4 adjusted EBITDA margins of 30% or more. So to summarize, Q2 was a strong quarter for definitive healthcare and we're well positioned to carry that strength into the remainder of 2022 and beyond. We've developed a clear leadership position in a large and attractive market that we believe will support high levels of predictable revenue growth and profitability for the foreseeable future. We believe we have built a unique business that can deliver strong growth at scale and do so in a capital efficient manner. We feel very good about the opportunity definitive health care has to become a much larger, more valuable business for our shareholders over time.

And with that, we can open the call to questions.

Thank you.

At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in a question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions.

The first questions

comes from the line of Craig Haddenbatch with Morgan Stanley. Please go ahead.

Yes, thank you. I appreciate the color on new customer wins and activity. Can you just maybe expand upon that, particularly on the upsell efforts and as it relates to your increased sales coverage? So as sales are able to focus on a small number of accounts as we go forward, how do you think that plays into the ability to you know, increase upsell traction with customers?

Yeah, thanks for the question. Appreciate it. We have, you know, as you know, so we verticalized our teams about three years ago and we verticalized our account executive team and our customer success team who works with existing accounts about a year and a half ago now. which was an important transition for us. And at the same time, as you said, we've reduced the number of companies that each of them sell to. So we're finding that to be very, very helpful from an upsell standpoint. So they're able to understand the customers better and then spend a lot more time working with different functions and different therapeutic areas within life sciences companies in particular. So we're in the early stages of that, but we're seeing benefits already. And we think as we continue to innovate and create new opportunities to expand with those customers, that strategy is going to pay off.

I appreciate that. And just as a follow-up, one area of concern that we have heard is just, you know, the funding environment in biotech given the lack of capital markets activity. Can you just touch on kind of how that, you know, potentially plays into your business and any influence you're seeing in terms of bookings and engagements on the biotech side? Sure.

So as Rick said, we had an extremely strong Q1, and that strength was really across all customer segments. So what I think is really great about our business is we sell to anybody that wants to sell and compete in health care. So we sell to life sciences, but we also sell to HCIT providers, and then all the companies, diversified companies that sell to many industries, including health care. So we have a tremendous amount of diversity in our client base, which is great. But we've seen strength in all of the areas, both on the new logo side as well as upsell side. So, you know, we're excited about where we're going really across the entire business.

Got it. Thanks.

Thank you. The next question comes from the line of DJ Hines with Canaccord. Please go ahead.

Hey, good afternoon, guys. Jason, Robert, congrats to you guys on the expanded roles. But maybe that's a good place to start. Jason, I'd love to get just any additional color on kind of your thinking that went into the transition and why it was kind of now the right time to do it.

Yeah, thanks. Great question. I think now is actually the perfect time to do it. So, you know, obviously we're lucky enough to have Robert and to start to build that partnership with him over the last year or so. Robert's an amazing leader with tremendous experience in SaaS-based businesses within healthcare. We're really excited about that. The business is performing fantastically right now. We're doing well. We have a great strategy. We've got a really good product vision to continue to execute upon. So all of that makes for a really great time. And then from a management structure across the entire company, our ELT is really strong. We've built that up over the last three years or so, and we've invested heavily in management throughout the entire organization. So It puts us in a great position to make this transition, and it allows me to spend more of my time on areas that I'm super passionate about. So product development and strategy, I'll definitely lean in more on M&A as that continues to be an important part of our business over time. So there's some real upsides as we get to partner in a slightly different way over the coming years. Yeah, that makes sense and great to hear.

Maybe a follow-up on analytical wizards. Thank you. you know, the, the press release and you've talked about in the past, some, some really big customer exposure, right? Six, 10 top pharma for the seven top biotechs where most of these customers already pulling definitive data into analytical, analytical wizards before the deal, or does the acquisition kind of, you know, materially change your opportunity with these large customers?

It really varies. Some of them do and some of them don't, and that's okay. What Analytical Wizards brings to us is our ability to be data agnostic and be able to take data from all different parts of the healthcare ecosystem. And clients can choose to pull in definitive data with that. Many of these clients obviously use our best-in-class affiliations data and our reference data and increasing their claims data as well. And we see that, you know, continue to expand over time. But the fact that we can bring in other data, internal data and third-party data, is just a tremendous new capability for us as we look to increase our presence in large pharmaceutical companies. Yeah, sounds good. Thank you, guys.

Thank you.

Thank you. The next question comes from the line of Jonathan Young with Credit Suisse. Please go ahead.

Hey, thanks for taking my question and congrats, Robert and Jason for the rules as well. Just in relation following up on Craig's question just in relation to the current macro environment. Based on your results. It doesn't look like things are slowing down and still looks pretty strong. I guess have conversations involved with new and existing customers. And if that's leading to kind of new or expanded opportunities or more or less just any commentary there.

I don't think we've seen a tremendous change.

In addition to selling to a wide variety of customers, our customers are using our data to drive growth and to figure out ways to do that more effectively and efficiently. We have a tremendous ROI with our clients, so I think that exists in all different market environments, especially in healthcare. You know, it's interesting. If you think back to 2020, so COVID hit, and that essentially shut down healthcare as we know it. And all of our clients are involved in healthcare in that way. And in that year, you know, I think we grew 38% in that year. So I think it just gives a sense of the must-have. the nature of the data and the intelligence that we provide. So, you know, it's a tribute to what we're doing, and I think it bodes well as we go into various different environments in the future.

That's really helpful. And then just going back to the analytical wizards, I guess it's early days, and, you know, they did get the nice big win there. But I guess how has the pipeline been developing since the close? Has there been any openings on cross-sell opportunities or things of that nature? Thanks.

Yeah, it's been really great since closing. We've been thrilled, first of all, with the team and the expertise they bring around analytics. The integration is going quite well. We feel like the teams have worked together really cooperatively. On the pipeline question, where we're seeing a ton of interest, it's use cases around advanced analytics for targeting, things like brand optimization use cases, being able to pull various data points to measure campaign effectiveness across multiple channels, things like that. So I'd say the pipeline creation has been a whole new level of analytic requests for us in especially our larger biopharma clients. And it's been nice to see.

Great. Thanks.

Thank you.

Again, if you would like to ask a question, please press star 1 on your telephone keypad. The next question comes from the line of David Grossman with Stifel. Please go ahead.

Thank you. You know, I think this question has already come up a couple times, and so I thought I would just maybe ask it a little more directly, is that, you know, over the recent past or even historically, have you ever seen any cyclical components in your model? And if you have, you know, how would you rank them in relative importance?

We have not seen cyclical things happening within our business to date. So over the last 11 years, you know, obviously we've been growing very fast every single year throughout that, including, you know, as I mentioned in 2020, we grew 38%. So we haven't seen anything. So I think, you know, as you think about the tailwinds of our business, first of all, you have health care, which is a growing market, continued aging population. So it's just tremendous tailwinds with that. The second is the move towards more digital. People are trying to use data in more effective ways to drive sales productivity, drive marketing productivity, and reach their customers in better, more effective ways. All of those trends I think are really accelerating. So in different macro environments, I think we're going to continue to see those trends as tailwinds for us that will offset you know, any short-term changes that might be happening in the macro community.

And just one other, you know, macro question, Jason. You know, how does wage inflation kind of play into your model or your pricing model? Is that something that's fairly dynamic, or is it something that flows through on renewals? Or how should we think about that, given that you're ramping headcount fairly aggressively?

Yeah, so as we think about pricing, I think we've talked about this a little bit on past calls, but we did a pricing study a couple years ago, and we think we have a lot of pricing power in the marketplace. We think that our pricing The offerings that we have can sell for a much higher price. But we are taking a very methodical approach to capturing that. And we really do that in three ways. The first is our new logo prices go up every single year. So our ACV of a new logo has gone up double digits every single year. We would expect that to be the case again this year. In addition to that, at the time of IPO, there was about 60% of our contracts were in multi-year deals. The vast majority of them have price escalators automatically built in, which is above most inflation and, you know, kind of similar to current inflationary environment. And then at renewal time, the majority of time, we'll actually renew our clients for a higher dollar amount. And that's really reflective, you know, not only of just kind of inflation in general, but we just, we keep investing in the platform, bringing in new data sets, creating new, more powerful analytics, and insight for our clients, and we're able to chart more as a result. So that theme and that focus of our organization will continue through this environment.

On the cost side, we've talked a lot about our amazing culture. This is the sort of time when it really pays dividends, and we pay a lot of attention to the labor situation. As you point out, we're scaling quickly, and our outlook includes the impact of any expected inflation.

Great. Very helpful. Thank you.

Thank you.

Ladies and gentlemen, if you would like to ask a question, please press star 1 on your telephone keypad. Again, if you would like to ask a question, please press star 1 on your telephone keypad.

Just a last reminder if you would like to ask a question please press star 1 on your telephone keypad.

As we have no further questions

Ladies and gentlemen, we have reached the end of question and answer session. And I would like to turn the call back to Jason Krantz for closing remarks. Thank you.

Jason Krantz Thanks. Once again, I just want to thank everybody for joining us today and listening to the earnings call. You know, once again, we couldn't be more excited about what we've created. We have a highly differentiated product that we continue to invest in and deep in that competitive mode over time and playing in a big market, a $10 billion plus market with that type of product is something we're excited about. So we think we're in a great position to continue to produce results like we did this quarter where we can drive long-term growth and profitability and want to thank everyone for their support and look forward to talking more with you.

Thank you. This concludes today's conference.

You may disconnect your lines at this time. Thank you for your participation.